§ Mr. SteenTo ask the Chancellor of the Exchequer what is his estimate of the total revenue raised from the imposition of value added tax on recombinant factor 8 used in the treatment of haemophiliacs. [15386]
§ Mr. Oppenheim[holding answer 12 February 1997]: The application of the standard rate of VAT to recombinant factor 8 is common to all manufactured drugs. It is estimated to raise approximately £1 million per year.